Cancer of the uterine cervix (CC) reflects disparities in access to healthcare across
the world; although being highly preventable, this disease is still a major public
health problem in less developed regions. Globally it is the second most prevalent
cancer in women, most cases being diagnosed at an advanced stage [
[1]
]. Inoperable CC will continue to be highly prevalent during the next decades as screening
programs and vaccination campaigns are still unavailable in most countries and are
not entirely effective. Currently, locally advanced disease is treated with (chemo)radiotherapy
and metastatic disease with platinum-based chemotherapy (±bevacizumab). First- and
second-line systemic treatments are not very effective, and early clinical trials
with targeted therapy have not yet identified new targeted drugs with superior response
rates [
[2]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics 2012.CA Cancer J Clin. 2015; 65: 87-108
- Cervical cancer: ESMO clinical practice guidelines.Ann Oncol. 2017; 28: iv72-iv83
- Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer.Eur J Cancer. 1998; 34: 341-346
- Cochrane Database Syst Rev. 2012 Dec 12; 12CD007406https://doi.org/10.1002/14651858.CD007406.pub3
- Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials.Eur J Cancer. 2003; 39: 2470-2486
- The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer.Gynecol Oncol. 2014 Aug; 134: 419-425https://doi.org/10.1016/j.ygyno.2014.06.001
- Review of neoadjuvant chemotherapy and trachelectomy: which cervical cancer patients would be suitable for neoadjuvant chemotherapy followed by fertility-sparing surgery?.Curr Oncol Rep. 2015; 17: 446https://doi.org/10.1007/s11912-015-0446-0
- Prognostic value of pathological response to neoadjuvant chemotherapy in bulky stage Ib2 and IIa cervical squamous cell cancer patients.Virchows Arch. 2016 Mar; 468 (Epub 2015 Dec 4): 329-336https://doi.org/10.1007/s00428-015-1888-3
- Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis and proliferation a s determinants of response to therapy and disease outcome.Am J Clin Pathol. 2001; 116: 729-737
- Simultaneous changes of magnetic resonance diffusion-weighted imaging and pathological microstructure in locally advanced cervical cancer caused by neoadjuvant chemotherapy.J Magn Reson Imaging. 2015 Aug; 42: 427-435https://doi.org/10.1002/jmri.24779
Article info
Publication history
Published online: September 27, 2017
Accepted:
September 1,
2017
Identification
Copyright
© 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
